VRPX Virpax Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRPX

Price (delayed)

$2.24

Market cap

$2.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.97

Enterprise value

-$6.52M

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug ...

Highlights
The EPS has grown by 30% YoY but it has contracted by 11% from the previous quarter
Virpax Pharmaceuticals's net income has increased by 30% YoY but it has decreased by 12% from the previous quarter
The equity has plunged by 88% YoY and by 70% from the previous quarter
Virpax Pharmaceuticals's quick ratio has plunged by 81% YoY and by 36% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://virpaxpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VRPX
Market
Shares outstanding
1.17M
Market cap
$2.62M
Enterprise value
-$6.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$15.19M
EBITDA
-$15.19M
Free cash flow
-$9.85M
Per share
EPS
-$12.97
Free cash flow per share
-$8.41
Book value per share
$1.65
Revenue per share
$0
TBVPS
$8.22
Balance sheet
Total assets
$9.63M
Total liabilities
$7.69M
Debt
$0
Equity
$1.93M
Working capital
$1.93M
Liquidity
Debt to equity
0
Current ratio
1.25
Quick ratio
1.19
Net debt/EBITDA
0.6
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-106.4%
Return on equity
-169%
Return on invested capital
N/A
Return on capital employed
-785.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRPX stock price

How has the Virpax Pharmaceuticals stock price performed over time
Intraday
2.28%
1 week
-27.51%
1 month
-46.15%
1 year
239.91%
YTD
-30.02%
QTD
-47.43%

Financial performance

How have Virpax Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.69M
Net income
-$15.19M
Gross margin
N/A
Net margin
N/A
Virpax Pharmaceuticals's net income has increased by 30% YoY but it has decreased by 12% from the previous quarter
VRPX's operating income is up by 28% year-on-year but it is down by 11% since the previous quarter

Growth

What is Virpax Pharmaceuticals's growth rate over time

Valuation

What is Virpax Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 30% YoY but it has contracted by 11% from the previous quarter
The equity has plunged by 88% YoY and by 70% from the previous quarter
The P/B is 4.6% above the last 4 quarters average of 1.3

Efficiency

How efficient is Virpax Pharmaceuticals business performance
The company's return on equity has shrunk by 86% YoY and by 57% QoQ
The ROA has contracted by 32% YoY and by 31% from the previous quarter

Dividends

What is VRPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRPX.

Financial health

How did Virpax Pharmaceuticals financials performed over time
The total assets is 25% more than the total liabilities
Virpax Pharmaceuticals's total liabilities has soared by 149% YoY and by 18% from the previous quarter
Virpax Pharmaceuticals's quick ratio has plunged by 81% YoY and by 36% from the previous quarter
Virpax Pharmaceuticals's debt is 100% less than its equity
The equity has plunged by 88% YoY and by 70% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.